{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061505","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.967872+00:00","generated_at":"2026-06-08T06:53:52.575772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amylyx reports Q3 product revenue $102.7M, net income $20.9M, PHOENIX topline Q2 2024","bullets":["Net product revenue $102.7M (Q3) vs $98.2M (Q2 2023) and $0.3M (Q3 2022).","Net income $20.9M ($0.30 diluted EPS) compared to net loss $53.8M in Q3 2022.","Cash, equivalents and short-term investments $355.0M at Sept 30, 2023.","Post hoc analysis: median overall survival 10.4 months longer with AMX0035 vs historical control.","CHMP reaffirmed negative EU opinion; final decision end 2023. PHOENIX Phase 3 topline expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061505","json":"https://secwatch.observer/filing/0000950170-23-061505.json","markdown":"https://secwatch.observer/filing/0000950170-23-061505.md","text":"https://secwatch.observer/filing/0000950170-23-061505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/0000950170-23-061505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/amlx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:53:52.575772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c019def845fb5f602637e9d0d033474ab30d1723","claim":"Amylyx Pharmaceuticals, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $102.7 million, net income $20.9 million, EPS $0.30 on a fully diluted per share basis.","evidence_excerpt":"in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results ˗ Third quarter 2023 product revenue of $102.7 million; bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch ˗ Strong financial position supported by $20.9 million of net income during the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023061505/0000950170-23-061505-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$102.7 million"},{"label":"Net income","value":"$20.9 million"},{"label":"EPS","value":"$0.30 on a fully diluted per share basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}